

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

**RE-ELECTIONS, APPOINTMENTS AND RE-APPOINTMENTS
RELATING TO THE BOARD, BOARD COMMITTEES AND
SENIOR MANAGEMENT; ELECTION OF
LEAD INDEPENDENT NON-EXECUTIVE DIRECTOR**

Reference is made to the circular of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated March 25, 2026 (the “**Circular**”), the poll results announcement of the Company dated April 28, 2026 (the “**Announcement**”), in relation to, among others, the re-election of Directors of the fourth session of the board of Directors (the “**Board**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular and the Announcement.

The Board hereby announces that on April 28, 2026, at the first meeting of the fourth session of the Board, the Board has resolved and approved the re-elections, appointments and re-appointments relating to the Board, Board committees and senior management of the Company, all with effect from April 28, 2026. Details of these resolutions are set forth below.

1. Re-election of the chairman of the Board

The Board has resolved and approved the re-election of Dr. Ge Li (李革) as the chairman of the fourth session of the Board with effect from April 28, 2026 until the expiry of the term of the fourth session of the Board.

Biographical details of Dr. Ge Li are set out in the Circular. As at the date of this announcement, there has been no change to such information.

2. Re-appointment of president and chief executive officer of the Company

The Board has resolved and approved the re-appointment of Dr. Ge Li as the president and chief executive officer of the Company with effect from April 28, 2026 until the expiry of the term of the fourth session of the Board.

3. Re-appointments of co-chief executive officers

The Board has resolved and approved the re-appointments of Dr. Minzhang Chen (陳民章) and Dr. Steve Qing Yang (楊青) as the co-chief executive officers of the Company with effect from April 28, 2026 until the expiry of the term of the fourth session of the Board.

Biographical details of Dr. Minzhang Chen and Dr. Steve Qing Yang are set out in the Circular. As at the date of this announcement, there has been no change to such information.

4. Re-appointment and appointment of vice presidents

The Board has resolved and approved the re-appointment and appointment of Mr. Zhaohui Zhang (張朝暉) and Dr. Hao Wu (吳皓) as the vice presidents of the Company with effect from April 28, 2026 until the expiry of the term of the fourth session of the Board.

Biographical details of Mr. Zhaohui Zhang are set out in the Circular. As at the date of this announcement, there has been no change to such information.

The biographical details of Dr. Hao Wu are as follows.

Dr. Hao Wu (吳皓), aged 52, is the general counsel and global head of human resources of the Company. Over 20 years of rich experience in the fields of legal, compliance management and cross region management in the related areas. Before joining the Company, Dr. Wu was general manager of legal department for the China region at Sinar Mas Group — Asia Pulp & Paper, and served as chief compliance counsel for GE Healthcare Greater China region, general counsel for Momentive Performance Material Asia Pacific region and a practicing lawyer in the US.

Dr. Wu received Juris Doctor degree from School of Law of University of the District of Columbia.

As at the date of this announcement, Dr. Wu was interested in 102,898 H Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”), and serves as directors of certain subsidiaries of the Company.

Save as disclosed above, as at the date of this announcement, Dr. Wu (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) has not held any other positions with the Company or other members of the Group; (iii) has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years; (iv) does not have any other major appointments and professional qualifications; (v) does not have any relationship with any Director, senior management or substantial or controlling shareholders of the Company; (vi) has no other information that needs to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules; and (vii) has no other matter that needs to be brought to the attention of the Shareholders.

5. Re-appointment of chief financial officer

The Board has resolved and approved the re-appointment of Ms. Ming Shi (施明) as the chief financial officer of the Company with effect from April 28, 2026 until the expiry of the term of the fourth session of the Board.

Biographical details of Ms. Ming Shi are set out in the 2025 annual report of the Company. As at the date of this announcement, there has been no change to such information.

6. Appointment of Board secretary

The Board has resolved and approved the appointment of Ms. Min Han (韓敏) as the Board secretary of the Company with effect from April 28, 2026 until the expiry of the term of the fourth session of the Board.

Biographical details of Ms. Min Han are set out in the 2025 annual report of the Company. As at the date of this announcement, there has been no change to such information.

7. Re-elections of members of the Board committees

The Board has resolved and approved the re-elections of the various members to the four Board committees of the fourth session of the Board as follow:

Strategy Committee

Dr. Ge Li (李革) (*Chairperson*)
Dr. Minzhang Chen (陳民章)
Mr. Xiaomeng Tong (童小幪)
Dr. Yibing Wu (吳亦兵)
Dr. Wei Yu (俞衛)

Nomination Committee

Mr. Xuesong Leng (冷雪松) (*Chairperson*)
Dr. Ge Li (李革)
Ms. Zhiling Zhan (詹智玲)

Audit Committee

Ms. Christine Shaohua Lu-Wong (盧韶華) (*Chairperson*)
Dr. Wei Yu (俞衛)
Dr. Xin Zhang (張新)

Remuneration and Appraisal Committee

Ms. Zhiling Zhan (詹智玲) (*Chairperson*)
Dr. Xin Zhang (張新)
Mr. Xuesong Leng (冷雪松)

Each of the term of office of committee members in their respective Board committees will be effective from April 28, 2026 until the expiry of the term of the fourth session of the Board.

Save as disclosed above, there are no other matters concerning the abovementioned re-elections, appointments and re-appointments relating to the Board, Board committees and senior management of the Company which would require disclosure under Rule 13.51(2) of the Listing Rules or matters which ought to be brought to the attention of the Shareholders and the Stock Exchange.

8. Election of lead independent non-executive Director

The Board is pleased to announce that with effect from April 28, 2026, Dr. Wei Yu will be elected as the lead independent non-executive Director (the “**Lead INED**”) to (i) serve as an intermediary for the other Directors and shareholders of the Company; and (ii) be available to other Directors and shareholders of the Company where normal communication channels with the chairman of the Board or management of the Company are inadequate. The Lead INED is not an executive position in the Company and does not have any management role in the Group, and will not have a separate or higher level of responsibility or liability relative to the other independent non-executive Directors.

By Order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, April 28, 2026

As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

* For identification purposes only